(Q45041460)

8 December 2017

title

Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas (English)

1 reference

8 December 2017

An J

1

1 reference

8 December 2017

Sun Y

series ordinal

2

1 reference

8 December 2017

Fisher M

series ordinal

3

1 reference

8 December 2017

Rettig MB

series ordinal

4

1 reference

8 December 2017

publication date

1 October 2004

1 reference

8 December 2017

1 reference

8 December 2017

volume

18

1 reference

8 December 2017

issue

10

1 reference

8 December 2017

page(s)

1699-1704

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403460

8 December 2017

exact match

0 references

cites work

The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

The proteasome in cancer biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

The proteasome--an emerging therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

inferred from DOI database lookup

7 January 2021

based on heuristic

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403460

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403460

1 reference

Dimensions Publication ID

8 December 2017

1004682309

0 references

1 reference